Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization

Neoplasia (United States)

Volumn 14, Issue 11, 2012, Pages 994-1004

  Nunez Cruz, Selene ^a   Gimotty, Phyllis A ^a   Guerra, Matthew W ^a   Connolly, Denise C ^b   Wu, You Qiang ^a   DeAngelis, Robert A ^a   Lambris, John D ^a   Coukos, George ^a   Scholler, Nathalie ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD45 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A RECEPTOR; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT INHIBITION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MICROVASCULATURE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 84869189833     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121262     Document Type: Article

References (65)

1. Coussens LM and Werb Z (2002). Inflammation and cancer. Nature 420, 860-867.
2. Balkwill F and Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet 357, 539-545.
3. Thun MJ, Henley SJ, and Patrono C (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94, 252-266.
4. Cipriano C, Giacconi R, Muzzioli M, Gasparini N, Orlando F, Corradi A, Cabassi E, and Mocchegiani E (2003). Metallothionein (I+II) confers, via c-myc, immune plasticity in oldest mice: model of partial hepatectomy/liver regeneration. Mech Ageing Dev 124, 877-886.
5. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, et al. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10, 501-507.
6. Ness RB, Goodman MT, Shen C, and Brunham RC (2003). Serologic evidence of past infection with Chlamydia trachomatis, in relation to ovarian cancer. J Infect Dis 187, 1147-1152.
7. Merritt MA, Green AC, Nagle CM, and Webb PM (2008). Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122, 170-176.
8. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, and Lokshin AE (2005). Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14, 981-987.
9. Auersperg N, Wng AS, Choi KC, Kang SK, and Leung PC (2001).Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22, 255-288.
10. Knutson KL, Curiel TJ, Salazar L, and Disis ML (2003). Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol Oncol Clin North Am 17, 1051-1073.
11. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, and Wilson JL (2005). The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65, 10355-10362.
12. Bjorge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE, and Meri S (2005). Ascitic complement system in ovarian cancer. Br J Cancer 92, 895-905.
13. Markiewski MM and Lambris JD (2007). The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171, 715-727.
14. Ricklin D, Hajishengallis G, Yang K, and Lambris JD (2010). Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11, 785-797.
15. Oikonomopoulou K, Ricklin D, Ward PA, and Lambris JD (2012). Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol 34, 151-165.
16. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, and Lambris JD (2008). Modulation of the antitumor immune response by complement. Nat Immunol 9, 1225-1235.
17. Cortright DN, Meade R, Waters SM, Chenard BL, and Krause JE (2009). C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells. Curr Eye Res 34, 57-61.
18. Yanai R, Thanos A, and Connor KM (2012). Complement involvement in neovascular ocular diseases. Adv Exp Med Biol 946, 161-183.
19. Girardi G, Yarilin D, Thurman JM, Holers VM, and Salmon JE (2006). Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 203, 2165-2175.
20. Lynch AM and Salmon JE (2010). Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 31, 561-567.
21. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ, et al. (2006). Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 103, 2328-2333.
22. van der Bilt AR, de Vries EG, de Jong S, Timmer-Bosscha H, van der Zee AG, and Reyners AK (2012). Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Crit Rev Oncol Hematol, E-pub ahead of print April 21.
23. Mattei MG, Borg JP, Rosnet O, Marme D, and Birnbaum D (1996). Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Genomics 32, 168-169.
24. Roskoski R Jr (2007). Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62, 179-213.
25. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, and Abraham JA (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266, 11947-11954.
26. Grunstein J, Masbad JJ, Hickey R, Giordano F, and Johnson RS (2000). Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol 20, 7282-7291.
27. Ferrara N (2000). Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55, 15-35; discussion 35-16.
28. Cheng SY, Nagane M, Huang HS, and Cavenee WK (1997). Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 94, 12081-12087.
29. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, and Bicknell R (2000). The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 83, 63-68.
30. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, et al. (1998). Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77, 998-1002.
31. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, and Lee YC (2001). Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19, 432-441.
32. Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, and Mueller V (2010). TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer 10, 139.
33. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365, 2484-2496.
34. Circolo A, Garnier G, Fukuda W, Wang X, Hidvegi T, Szalai AJ, Briles DE, Volanakis JE, Wetsel RA, and Colten HR (1999). Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology 42, 135-149.
35. Hopken UE, Lu B, Gerard NP, and Gerard C (1996). The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383, 86-89.
36. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, and Hamilton TC (2003). Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63, 1389-1397.
37. Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, and Connolly DC (2007). Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther 6, 1717-1725.
38. Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, and Connolly DC (2010). Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res 3, 24.
39. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92, 3439-3443.
40. Hanahan D (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122.
41. Grippo PJ and Sandgren EP (2000). Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol 157, 805-813.
42. Chailley-Heu B, Rambaud C, Barlier-Mur AM, Galateau-Salle F, Perret C, Capron F, and Lacaze-Masmonteil T (2001). A model of pulmonary adenocarcinoma in transgenic mice expressing the simian virus 40 T antigen driven by the rat Calbindin-D9K (CaBP9K) promoter. J Pathol 195, 482-489.
43. Bergers G, Javaherian K, Lo KM, Folkman J, and Hanahan D (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.
44. Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
45. Nozawa H, Chiu C, and Hanahan D (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103, 12493-12498.
46. Du YC, Lewis BC, Hanahan D, and Varmus H (2007). Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol 5, e276.
47. Aunoble B, Sanches R, Didier E, and Bignon YJ (2000). Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 16, 567-576.
48. Feeley KM and Wells M (2001). Precursor lesions of ovarian epithelial malignancy. Histopathology 38, 87-95.
49. Dodson MK, Cliby WA, Xu HJ, DeLacey KA, Hu SX, Keeney GL, Li J, Podratz KC, Jenkins RB, and Benedict WF (1994). Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res 54, 610-613.
50. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T, Ishiko O, and Ogita S (2001). Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 32, 988-996.
51. Chow WN, Lee YL, Wong PC, Chung MK, Lee KF, and Yeung WS (2009). Complement 3 deficiency impairs early pregnancy in mice. Mol Reprod Dev 76, 647-655.
52. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226-230.
53. Medford AR, Douglas SK, Godinho SI, Uppington KM, Armstrong L, Gillespie KM, van Zyl B, Tetley TD, Ibrahim NB, and Millar AB (2009). Vascular endothelial growth factor (VEGF) isoform expression and activity in human and murine lung injury. Respir Res 10, 27.
54. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, and Campani D (2004). Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57, 630-636.
55. de Visser KE, Korets LV, and Coussens LM (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423.
56. Wetsel RA (1995). Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. Immunol Lett 44, 183-187.
57. Gasque P, Singhrao SK, Neal JW, Gotze O, and Morgan BP (1997). Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 150, 31-41.
58. Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, and Lambris JD (2010). Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol 48, 481-489.
59. Stove S, Welte T, Wagner TO, Kola A, Klos A, Bautsch W, and Kohl J (1996). Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3, 175-183.
60. Eatock MM, Schatzlein A, and Kaye SB (2000). Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 26, 191-204.
61. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, and Guyer DR (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351, 2805-2816.
62. Finley SD and Popel AS (2012). Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J 14, 500-509.
63. Langer HF, Chung KJ, Orlova VV, Choi EY, Kaul S, Kruhlak MJ, Alatsatianos M, DeAngelis RA, Roche PA, Magotti P, et al. (2010). Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 116, 4395-4403.
64. Pereira R, Halford K, Sokolov BP, Khillan JS, and Prockop DJ (1994). Phenotypic variability and incomplete penetrance of spontaneous fractures in an inbred strain of transgenic mice expressing a mutated collagen gene (COL1A1). J Clin Invest 93, 1765-1769.
65. Li D, Yu J, Gu F, Pang X, Ma X, Li R, and Liu N (2008). The roles of two novel FBN1 gene mutations in the genotype-phenotype correlations of Marfan syndrome and ectopia lentis patients with marfanoid habitus. Genet Test 12, 325-330.